MCLA 117

Drug Profile

MCLA 117

Alternative Names: MCLA-117

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merus
  • Developer Institute Gustave-Roussy; LGC; Merus; Pharmaceutical Research Associates; VU University Medical Center
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action C-type lectin-like molecule-1 protein modulators; CD3 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Preclinical Myelodysplastic syndromes

Most Recent Events

  • 19 Sep 2017 Merus has patent protection for Biclonics® technology in USA
  • 19 Sep 2017 Merus announces intention to submit IND application to US FDA for a phase I trial of MCLA 117 in fourth quarter of 2017
  • 22 Aug 2017 Merus has patent protection for Biclonics® technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top